Table 1 Clinical ASD gene sequencing panels available as of June 2018

From: Heterogeneity in clinical sequencing tests marketed for autism spectrum disorders

Number

Laboratory company

Test name

Number of genes included

Gene list provideda

Gene selection criteria/rationale providedb

Certification/accreditation notes providedb

1

Ambry Genetics

AutismNext

48

●

●

●

2

ApolloGen

Autism Spectrum Disorders Panel Test

125

●

 

●

3

Asper Biogene Asper Biogene LLC

Autism Spectrum Disorders NGS panel

52

●

 

●

4

Ayass BioScience

AUTISM – Genetic Testing

98

○

●

●

5

Blueprint Genetics

Autism Spectrum Disorder Panel

26

●

●

●

6

CEN4GEN

Autism Spectrum Disorders: Gene Panel

63

●

  

7

Center for Human Genetics, Inc

Autism Spectrum Disorders 53-Gene Panel

53

●

●

●

8

Centogene

Syndromic autism panel

50

●

●

●

9

CGC Genetics

Autism

28

●

●

●

10

EGL Genetic Diagnostics (Emory)

Autism Spectrum Disorders: Tier 2 Panel

63

●

 

●

11

Fulgent Genetics

Autism NGS Panel

106

●

 

●

12

GeneDx

Autism/ID Xpanded Panel

2562

●

●

●

13

GENETAQ

Autism

28

●

 

●

14

Greenwood Genetic Center Diagnostic Laboratories

Syndromic Autism Sequencing Panel

83

●

●

●

15

Munroe-Meyer Institute

Autism/Intellectual Disability/Multiple Anomalies Panel

117

●

●

●

16

Lineagen

NextStepDx PLUS

936

○

●

 

17

Michigan Medical Genetics Laboratories

Autism / Intellectual Disability Panels (Tier 2 and Tier 3)

11

●

●

●

18

MNG Laboratories

Comprehensive Intellectual Disability/Autism

901

●

●

●

19

PreventionGenetics

Autism Spectrum Disorders and Intellectual Disability (ASD-ID) Comprehensive Sequencing Panel with CNV Detection AND

1908

●

●

●

Autism Spectrum Disorders Sequencing Panel with CNV Detection

108

20

Reference Laboratory Genetics

Autism Spectrum Disorders (Expanded Panel)

77

●

 

●

21

Sema4

Autism Spectrum Disorder Sequencing Panel

30

●

 

●

  1. ○ = provided upon request
  2. aSee Supplementary Table S1 for full gene list
  3. bSee Supplementary Table S5 for details
Back to article page